Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Accounts Payables: 2021-2024

Historic Accounts Payables for Krystal Biotech (KRYS) over the last 4 years, with Dec 2024 value amounting to $59.0 million.

  • Krystal Biotech's Accounts Payables fell 40.31% to $31.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $31.7 million, marking a year-over-year decrease of 40.31%. This contributed to the annual value of $59.0 million for FY2024, which is 174.23% up from last year.
  • Per Krystal Biotech's latest filing, its Accounts Payables stood at $59.0 million for FY2024, which was up 174.23% from $21.5 million recorded in FY2023.
  • In the past 5 years, Krystal Biotech's Accounts Payables registered a high of $59.0 million during FY2024, and its lowest value of $16.3 million during FY2021.
  • Moreover, its 3-year median value for Accounts Payables was $23.3 million (2022), whereas its average is $34.6 million.
  • Per our database at Business Quant, Krystal Biotech's Accounts Payables dropped by 7.70% in 2023 and then skyrocketed by 174.23% in 2024.
  • Over the past 4 years, Krystal Biotech's Accounts Payables (Yearly) stood at $16.3 million in 2021, then skyrocketed by 43.00% to $23.3 million in 2022, then dropped by 7.70% to $21.5 million in 2023, then spiked by 174.23% to $59.0 million in 2024.